Arcturus Therapeutics Holdings Inc.(ARCT)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,943 of 2,962 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
ARCT Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for Arcturus Therapeutics Holdings Inc. (ARCT), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ARCT at 7.5/100 on a 32-signal composite quality model, placing it at rank #2,943 of 2,962 stocks — the bottom half of the AI-ranked universe. Areas of concern include revenue growth (0.3) and free cash flow (4.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 6.1/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Arcturus Therapeutics Holdings Inc. reports quarterly revenue of $3.0M, net income of $-23.8M, free cash flow of $-19.9M. Top institutional holders of ARCT by reported 13-F value include FEDERATED HERMES, ARK Investment Management, BlackRock, based on the most recent SEC filings. ARCT trades on the Nasdaq exchange and files with the SEC under CIK 1768224. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ARCT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Arcturus Therapeutics Holdings Inc. directly from SEC EDGAR. Arcturus Therapeutics Holdings Inc.'s 13F Pro composite quality score has ranged between 6 and 41 since 2021, currently 7.5 — a declining long-term trajectory across 68 quarterly and live scoring snapshots.
Revenue
Q2 2026
$3.0M
Net Income
Q2 2026
$-23.8M
Free Cash Flow
Q2 2026
$-19.9M
ROIC
Q2 2026
-59.5%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
-46.1% YoYNet Income
+18.7% YoYOperating Income
+20.3% YoYEPS (Diluted)
+20.0% YoYTotal Assets
-21.2% YoYTotal Debt
Op. Cash Flow
-24.3% YoYFree Cash Flow
-23.4% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $82.0M -46.1% | $152.3M -8.7% | $166.8M -19.0% | $206.0M +1566.8% | $12.4M +29.6% | $9.5M |
| Net Income | $-65.8M +18.7% | $-80.9M -172.3% | $-29.7M -417.9% | $9.3M +104.6% | $-203.7M -182.3% | $-72.1M |
| Operating Income | $-76.3M +20.3% | $-95.7M -22.3% | $-78.2M -742.2% | $12.2M +106.0% | $-202.9M -183.6% | $-71.5M |
| EPS (Diluted) | $-2.40 +20.0% | $-3.00 -167.9% | $-1.12 -420.0% | $0.35 +104.5% | $-7.74 | — |
| Total Assets | $271.1M -21.2% | $344.1M -19.9% | $429.4M -4.7% | $450.4M +14.7% | $392.8M -17.6% | $476.5M |
| Total Debt | — | — | — | $60.7M -3.9% | $63.1M +281.3% | $16.6M |
| Operating Cash Flow | $-74.3M -24.3% | $-59.7M -230.1% | $-18.1M -156.6% | $32.0M +123.7% | $-135.0M -215.1% | $-42.9M |
| Free Cash Flow | $-74.5M -23.4% | $-60.4M -187.6% | $-21.0M -186.5% | $24.3M +117.5% | $-138.4M -210.4% | $-44.6M |
Get alerted when ARCT's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Arcturus Therapeutics Holdings Inc. including:
Top Institutional Holders of ARCT
FEDERATED HERMES, INC.
$22.2M3,303,640 shARK Investment Management LLC
$19.5M2,901,635 shBlackRock, Inc.
$17.6M2,614,012 shSumitomo Mitsui Trust Holdings, Inc.
$13.2M1,963,123 shNikko Asset Management Americas, Inc.
$13.1M1,960,458 shVANGUARD CAPITAL MANAGEMENT LLC
$7.5M1,114,956 shTWO SIGMA INVESTMENTS, LP
$7.3M1,091,137 shVANGUARD PORTFOLIO MANAGEMENT LLC
$6.4M951,575 shGEODE CAPITAL MANAGEMENT, LLC
$4.7M693,660 shAQR CAPITAL MANAGEMENT LLC
$4.5M675,014 sh
| Fund | Value | Shares |
|---|---|---|
| FEDERATED HERMES, INC. | $22.2M | 3,303,640 |
| ARK Investment Management LLC | $19.5M | 2,901,635 |
| BlackRock, Inc. | $17.6M | 2,614,012 |
| Sumitomo Mitsui Trust Holdings, Inc. | $13.2M | 1,963,123 |
| Nikko Asset Management Americas, Inc. | $13.1M | 1,960,458 |
| VANGUARD CAPITAL MANAGEMENT LLC | $7.5M | 1,114,956 |
| TWO SIGMA INVESTMENTS, LP | $7.3M | 1,091,137 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $6.4M | 951,575 |
| GEODE CAPITAL MANAGEMENT, LLC | $4.7M | 693,660 |
| AQR CAPITAL MANAGEMENT LLC | $4.5M | 675,014 |
Companies Similar to ARCT
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
Personalis, Inc.
Nurix Therapeutics, Inc.
Arbutus Biopharma Corp
OCULAR THERAPEUTIX, INC
Voyager Therapeutics, Inc.
Keros Therapeutics, Inc.
Wave Life Sciences, Inc.
CRISPR Therapeutics AG
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put ARCT on your watchlist
Track score changes the day Arcturus Therapeutics Holdings Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is ARCT a good stock to buy?
13F Pro's AI-powered analysis of Arcturus Therapeutics Holdings Inc. (ARCT) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ARCT are available on the ARCT stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. ARCT is classified as a small company.
Which hedge funds own ARCT?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ARCT. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Arcturus Therapeutics Holdings Inc.'s investment landscape.